DK81691A - Fremgangsmaade til forhindring eller reduktion af eosinofili - Google Patents

Fremgangsmaade til forhindring eller reduktion af eosinofili Download PDF

Info

Publication number
DK81691A
DK81691A DK081691A DK81691A DK81691A DK 81691 A DK81691 A DK 81691A DK 081691 A DK081691 A DK 081691A DK 81691 A DK81691 A DK 81691A DK 81691 A DK81691 A DK 81691A
Authority
DK
Denmark
Prior art keywords
eosinophilia
prevention
procedure
reduction
antagonist
Prior art date
Application number
DK081691A
Other languages
Danish (da)
English (en)
Other versions
DK81691D0 (da
Inventor
Robert L Coffman
Almond Avenue Los Alto Rennick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23016493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK81691(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of DK81691A publication Critical patent/DK81691A/da
Publication of DK81691D0 publication Critical patent/DK81691D0/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Head (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Pens And Brushes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK91816A 1988-11-03 1991-05-02 Fremgangsmaade til forhindring eller reduktion af eosinofili DK81691D0 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26690988A 1988-11-03 1988-11-03
PCT/US1989/004796 WO1990004979A2 (en) 1988-11-03 1989-11-01 Method of preventing or reducing eosinophilia

Publications (2)

Publication Number Publication Date
DK81691A true DK81691A (da) 1991-05-02
DK81691D0 DK81691D0 (da) 1991-05-02

Family

ID=23016493

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91816A DK81691D0 (da) 1988-11-03 1991-05-02 Fremgangsmaade til forhindring eller reduktion af eosinofili

Country Status (17)

Country Link
EP (2) EP0367596B1 (de)
JP (1) JPH07563B2 (de)
KR (1) KR960002183B1 (de)
AT (1) ATE98872T1 (de)
AU (1) AU633034B2 (de)
CA (1) CA2002144C (de)
DE (1) DE68911653T2 (de)
DK (1) DK81691D0 (de)
ES (1) ES2062032T3 (de)
HK (1) HK186196A (de)
IE (1) IE63063B1 (de)
IL (1) IL92180A (de)
MY (1) MY107386A (de)
NZ (1) NZ243939A (de)
PH (1) PH26476A (de)
WO (1) WO1990004979A2 (de)
ZA (1) ZA898322B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683836B2 (en) * 1992-02-06 1997-11-27 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
EP0681589A1 (de) * 1993-02-01 1995-11-15 Université Libre de Bruxelles Verwendung von pharmazeutischen zusammensetzungen, die interleukin-10 enthalten
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
DE69535319T2 (de) * 1994-12-23 2007-07-19 Smithkline Beecham Corp. Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
MXPA04009418A (es) * 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
MX2010010667A (es) 2008-03-28 2010-11-09 Glaxosmithkline Llc Metodos de tratamiento.
US11390671B2 (en) 2017-06-06 2022-07-19 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854741T3 (de) * 1987-06-24 2002-08-14 Autoimmune Inc Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.

Also Published As

Publication number Publication date
IL92180A (en) 1997-04-15
EP0441891A1 (de) 1991-08-21
AU4644889A (en) 1990-05-28
CA2002144C (en) 2000-03-28
EP0367596B1 (de) 1993-12-22
HK186196A (en) 1996-10-11
NZ243939A (en) 1997-07-27
CA2002144A1 (en) 1990-05-03
MY107386A (en) 1995-11-30
ATE98872T1 (de) 1994-01-15
JPH07563B2 (ja) 1995-01-11
DE68911653D1 (de) 1994-02-10
IE63063B1 (en) 1995-03-22
KR960002183B1 (ko) 1996-02-13
DE68911653T2 (de) 1994-04-07
IL92180A0 (en) 1990-07-26
AU633034B2 (en) 1993-01-21
ES2062032T3 (es) 1994-12-16
IE893525L (en) 1990-05-03
KR900701320A (ko) 1990-12-01
WO1990004979A8 (en) 2005-06-16
ZA898322B (en) 1990-11-28
EP0367596A1 (de) 1990-05-09
DK81691D0 (da) 1991-05-02
PH26476A (en) 1992-07-27
JPH03505211A (ja) 1991-11-14
WO1990004979A2 (en) 1990-05-17

Similar Documents

Publication Publication Date Title
DK183590D0 (da) Fremgangsmaade til reduktion af immunoglobulin e-responser
AU4688589A (en) A method for treatment of endotoxic shock in a mammal
DK81691D0 (da) Fremgangsmaade til forhindring eller reduktion af eosinofili
DK0504307T3 (da) Fremgangsmåde til behandling af septisk shock
FI862978A (fi) Onkofetaalisia spesifisiä monoklonaalisia vasta-aineita, menetelmä niiden valmistamiseksi ja niiden käyttö.
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
FI924278A0 (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment